VYGR * logo

Voyager Therapeutics BMV:VYGR * Stock Report

Last Price

Mex$165.00

Market Cap

Mex$7.4b

7D

0%

1Y

n/a

Updated

28 Oct, 2024

Data

Company Financials +

Voyager Therapeutics, Inc.

BMV:VYGR * Stock Report

Market Cap: Mex$7.4b

VYGR * Stock Overview

A biotechnology company, focuses on the human genetics for the cure of neurological diseases. More details

VYGR * fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings are forecast to decline by an average of 23.5% per year for the next 3 years

Shares are highly illiquid

Significant insider selling over the past 3 months

Profit margins (6.3%) are lower than last year (49.2%)

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Voyager Therapeutics, Inc. Competitors

PharmaEngine

TPEX:4162

NT$15.3b

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.3b

Ever Supreme Bio Technology

TPEX:6712

NT$14.6b

Rigel Pharmaceuticals

NasdaqGS:RIGL

US$360.8m

Price History & Performance

Summary of share price highs, lows and changes for Voyager Therapeutics
Historical stock prices
Current Share PriceUS$165.00
52 Week HighUS$167.00
52 Week LowUS$130.00
Beta0.91
1 Month Change0%
3 Month Change0%
1 Year Changen/a
3 Year Change106.25%
5 Year Change-42.46%
Change since IPO-67.95%

Recent News & Updates

Recent updates

Shareholder Returns

VYGR *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how VYGR * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how VYGR * performed against the MX Market.

Price Volatility

Is VYGR *'s price volatile compared to industry and market?
VYGR * volatility
VYGR * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: VYGR *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine VYGR *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013162Al Sandrockwww.voyagertherapeutics.com

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.

Voyager Therapeutics, Inc. Fundamentals Summary

How do Voyager Therapeutics's earnings and revenue compare to its market cap?
VYGR * fundamental statistics
Market capMex$7.35b
Earnings (TTM)Mex$180.22m
Revenue (TTM)Mex$2.87b

40.8x

P/E Ratio

2.6x

P/S Ratio

Is VYGR * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VYGR * income statement (TTM)
RevenueUS$143.77m
Cost of RevenueUS$113.16m
Gross ProfitUS$30.61m
Other ExpensesUS$21.58m
EarningsUS$9.02m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.17
Gross Margin21.29%
Net Profit Margin6.28%
Debt/Equity Ratio0%

How did VYGR * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/28 07:17
End of Day Share Price 2024/07/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Voyager Therapeutics, Inc. is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jack AllenBaird
Aydin HuseynovBenchmark Company